(MANE) Veradermics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NYSE (USA) | Market Cap: 2.299m USD | Total Return: 70% in 12m

Stock Hair Loss, Warts, Skin Conditions, Patches
Total Rating 48
Risk 49
Buy Signal 1.77
Biotechnology +0.2
Market Cap: 2,299m
Avg Trading Vol: 22.7M USD
ATR: 8.12%
Peers RS (IBD): 69.3
Risk 5d forecast
Volatility68.2%
Rel. Tail Risk4.28%
Reward TTM
Sharpe Ratio5.11
Alpha125.81
Character TTM
Beta-4.442
Beta Downside-3.274
Drawdowns 3y
Max DD15.79%
CAGR/Max DD185.69
EPS (Earnings per Share) EPS (Earnings per Share) of MANE over the last years for every Quarter: "2023-12": null, "2024-12": null,
Revenue Revenue of MANE over the last years for every Quarter: 2023-12: null, 2024-12: 0,
Rev. CAGR: 0.00%
Qual. Beats: 0
Description: MANE Veradermics

Veradermics, Incorporated (NYSE: MANE) is a biopharmaceutical company specializing in the development of therapeutics for high-demand dermatologic and aesthetic conditions. The company’s valuation thesis is largely anchored to VDPHL01, a non-hormonal oral treatment for Pattern Hair Loss; this asset targets a massive Total Addressable Market (TAM) by attempting to circumvent the adverse side effect profiles associated with legacy hormonal therapies.

The company further diversifies its clinical risk through a pipeline utilizing dissolvable microarray patch technology for indications such as common warts (VDMN) and alopecia areata (VDAA). As a development-stage biotech founded in 2019, MANEs stock performance will be primarily driven by binary clinical trial data readouts and subsequent regulatory milestones. To evaluate the specific financial health and cash runway of this clinical-stage entity, investors often consult ValueRay for deeper fundamental analysis.

Headlines to Watch Out For
  • VDPHL01 clinical trial results impact future revenue projections
  • Regulatory approval timelines for VDAA and VDMC affect market entry
  • Competition from established dermatology treatments limits market share
  • Healthcare provider adoption of novel therapies drives sales growth
Piotroski VR‑10 (Strict) 1.0
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -1.26 > 0.02 and ΔFCF/TA -52.82 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -1.26 > 3% & CFO -23.7m > Net Income -26.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.29 > 1.5 & < 3
Outstanding Shares: last fiscal year (201.3m) vs prev 0.0% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%)
Interest Coverage Ratio: -45.77 > 6 (EBITDA TTM -25.9m / Interest Expense TTM 585k)
Altman Z'' -15.00
A: 0.69 (Total Current Assets 18.7m - Total Current Liabilities 5.69m) / Total Assets 18.8m
B: -5.18 (Retained Earnings -97.4m / Total Assets 18.8m)
C: -1.44 (EBIT TTM -26.8m / Avg Total Assets 18.6m)
D: -0.85 (Book Value of Equity -97.4m / Total Liabilities 114.8m)
Altman-Z'' Score: -22.90 = D
Beneish M
DSRI: none (Receivables 1.23m/none, Revenue 0.0/0.0)
GMI: 1.00 (fallback, negative margins)
AQI: none (AQ_t none / AQ_t-1 none)
SGI: none (Revenue 0.0 / 0.0)
TATA: -0.15 (NI -26.5m - CFO -23.7m) / TA 18.8m)
Beneish M-Score: cannot calculate (missing components)
What is the price of MANE shares? As of April 03, 2026, the stock is trading at USD 63.15 with a total of 731,962 shares traded.
Over the past week, the price has changed by -4.97%, over one month by +37.69%, over three months by +70.04% and over the past year by +70.04%.
Is MANE a buy, sell or hold? Veradermics has no consensus analysts rating.
What are the forecasts/targets for the MANE price?
Wallstreet Target Price 78.3 24%
Analysts Target Price - -
MANE Fundamental Data Overview as of 03 April 2026
Revenue TTM = 0.0 USD
EBIT TTM = -26.8m USD
EBITDA TTM = -25.9m USD
Long Term Debt = 16.0k USD (from capitalLeaseObligations, last quarter)
 Short Term Debt = unknown (none)
 Debt = 16.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -5.64m USD (from netDebt column, last quarter)
Enterprise Value = 2.28b USD (2.30b + Debt 16.0k - CCE 15.1m)
Interest Coverage Ratio = -45.77 (Ebit TTM -26.8m / Interest Expense TTM 585k)
EV/FCF = -96.40x (Enterprise Value 2.28b / FCF TTM -23.7m)
FCF Yield = -1.04% (FCF TTM -23.7m / Enterprise Value 2.28b)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
 Tobins Q-Ratio = 121.5 (set to none) (Enterprise Value 2.28b / Total Assets 18.8m)
 Interest Expense / Debt = 3.66k% (Interest Expense 585k / Debt 16.0k)
 Taxrate = 21.0% (US default 21%)
NOPAT = -21.2m (EBIT -26.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.29 (Total Current Assets 18.7m / Total Current Liabilities 5.69m)
 Debt / Equity = -0.00 (negative equity) (Debt 16.0k / totalStockholderEquity, last quarter -96.0m)
 Debt / EBITDA = 0.22 (negative EBITDA) (Net Debt -5.64m / EBITDA -25.9m)
 Debt / FCF = 0.24 (negative FCF - burning cash) (Net Debt -5.64m / FCF TTM -23.7m)
 Total Stockholder Equity = 54.7m (last fiscal year from totalStockholderEquity)
 RoA = -142.2% (out of range, set to none)
 RoE = -48.46% (Net Income TTM -26.5m / Total Stockholder Equity 54.7m)
RoCE = -48.97% (EBIT -26.8m / Capital Employed (Equity 54.7m + L.T.Debt 16.0k))
 RoIC = 19.03% (negative operating profit) (NOPAT -21.2m / Invested Capital -111.1m)
 WACC = -9.64% (negative - check inputs) (E(2.30b)/V(2.30b) * Re(-9.64%) + (debt cost/tax rate unavailable))
 Discount Rate = 9.50% (= Risk Free + ERP)
Shares Correlation 3-Years: -100.0 | Cagr: -82.58%
 [DCF] Fair Price = unknown (Cash Flow -23.7m)
 Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=-2.75 | Chg7d=+0.000 | Chg30d=-2.754 | Revisions Net=+0 | Growth EPS=-27.1% | Growth Revenue=+0.0%
External Resources
Dataroma Stockcircle